Rare diseases
Investigational molecules
Locations
345 conditions with trials, the busiest first
956 trials across Europe, recruiting first
Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer
AustriaStudy on the Safety and Effectiveness of Crinecerfont for Children with Classic Congenital Adrenal Hyperplasia
BelgiumStudy of alpelisib and olaparib combination compared to chemotherapy in patients with platinum-resistant high-grade serous ovarian cancer without BRCA mutation
FinlandStudy on Olaparib for Patients with Advanced HER2-Negative Breast Cancer and Specific Genetic Mutations
SpainStudy on Adding Capecitabine to Carboplatin-Based Chemotherapy for Patients with Early Triple Negative Breast Cancer
DenmarkStudy on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer
FranceStudy on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
GermanyStudy of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer
BelgiumStudy on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer
BelgiumStudy of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer
FranceStudy of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer
BelgiumStudy of PF-07220060 and PF-07104091 with Endocrine Therapy for Patients with Advanced HR-positive HER2-negative Breast Cancer
BulgariaThe therapies tested most often in Reproductive system and breast disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
